financetom
Business
financetom
/
Business
/
MicroStrategy continues bitcoin buying spree, lifting holdings to $9.45 bln
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
MicroStrategy continues bitcoin buying spree, lifting holdings to $9.45 bln
Sep 13, 2024 12:09 PM

Sept 13 (Reuters) - Software firm MicroStrategy ( MSTR )

acquired bitcoin worth $1.11 billion between Aug. 6 and Sept 12,

boosting its total holdings of the world's biggest

cryptocurrency to roughly $9.45 billion.

WHY IT'S IMPORTANT

The approval of spot bitcoin exchange-traded funds by the

Securities and Exchange Commission in January along with support

from Wall Street and figures like Elon Musk has brought the

once-nascent asset class closer to the mainstream.

Analysts have said MicroStrategy's ( MSTR ) purchase of bitcoin to

protect the value of its reserve assets has helped strengthen

the appeal of the firm's stock, which tends to move in tandem

with the digital asset.

CONTEXT

MicroStrategy ( MSTR ) began buying and holding bitcoin in 2020 as

revenue from its software business eased, and it is now the

largest corporate holder of the cryptocurrency.

MicroStrategy ( MSTR ), which ended 2023 with 190,000 bitcoin on its

balance sheet, had indicated that it would increase its

exposure.

MicroStrategy's ( MSTR ) board of directors decided in favor of a

10-for-1 stock split in July, to make it more accessible to

investors.

BY THE NUMBERS

MicroStrategy ( MSTR ) bought about 18,300 bitcoins at an average

price of about $60,408 per bitcoin between Aug. 6 and Sept 12.

The company and its subsidiaries held about 244,800 bitcoins

as of Sept 12, 2024.

The total holding equates to about $9.45 billion,

representing an average purchase price of about $38,585 per

bitcoin, including fees and expenses.

MicroStrategy's ( MSTR ) shares have more than doubled in 2024, while

bitcoin has gained nearly 31% year-to-date.

GRAPHIC

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BBVA Research Sees Two 25bps Rate Cuts At Peru's Central Bank by End Q2 2025 After Last's Week Hold
BBVA Research Sees Two 25bps Rate Cuts At Peru's Central Bank by End Q2 2025 After Last's Week Hold
Dec 16, 2024
08:49 AM EST, 12/16/2024 (MT Newswires) -- The Board of Peru's central bank (BCRP) last week kept the reference interest rate at 5.00%, noted BBA Research. BCRP expected both headline and core inflation to remain within the target range over the projection horizon, pointed out BBVA Research. It also states that economic activity was now around its potential level. BBVA...
Regional lenders Berkshire Hills Bancorp, Brookline strike $1.1 bln merger deal
Regional lenders Berkshire Hills Bancorp, Brookline strike $1.1 bln merger deal
Dec 16, 2024
Dec 16 (Reuters) - Berkshire Hills Bancorp ( BHLB ) and Brookline Bancorp ( BRKL ) have agreed to merge in an all-stock deal valued at about $1.1 billion, the regional lenders said on Monday. Regional lenders that were at the heart of the banking crisis in 2023 have been cutting more deals this year to expand their geographic foothold...
Arcutis Biotherapeutics Submits Supplemental New Drug Application to FDA for Zoryve Cream
Arcutis Biotherapeutics Submits Supplemental New Drug Application to FDA for Zoryve Cream
Dec 16, 2024
08:47 AM EST, 12/16/2024 (MT Newswires) -- Arcutis Biotherapeutics ( ARQT ) said Monday it submitted a supplemental new drug application to the US Food and Drug Administration for Zoryve cream 0.05% for the treatment of mild to moderate atopic dermatitis in children aged 2 to 5 years. The cream demonstrated consistent, rapid relief and good tolerability in prior trials,...
Dare Bioscience to Submit Plan for Phase 3 Study of Potential Female Sexual Disorder Treatment
Dare Bioscience to Submit Plan for Phase 3 Study of Potential Female Sexual Disorder Treatment
Dec 16, 2024
08:50 AM EST, 12/16/2024 (MT Newswires) -- Dare Bioscience ( DARE ) and its partner Strategic Science & Technologies said Monday they will submit a protocol and statistical analysis plan to the US Food and Drug Administration in Q1 for a phase 3 study of sildenafil cream, 3.6%, an investigational treatment for female sexual arousal disorder. The companies said they...
Copyright 2023-2026 - www.financetom.com All Rights Reserved